Stifel Maintains Buy on BridgeBio Oncology, Lowers Price Target to $15
Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers the price target from $23 to $15.
An expert who studies stocks still thinks BridgeBio is worth buying, but thinks it might not be worth as much money as they thought before. When experts lower their price guess but keep saying 'buy,' it means they still see promise but are being more careful.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.